Abstract
Cancers assume a variety of distinct histologies and may originate from a myriad of sites including solid organs, hematopoietic cells, and connective tissue. Clinical decision making based on consensus guidelines such as NCCN is often predicated on a specific histologic and anatomic diagnosis, supported by clinical features and pathologist interpretation of morphology and immunohistochemical (IHC) staining patterns. However, in patients with nonspecific morphologic and IHC findings—in addition to ambiguous clinical presentations such as recurrence versus new primary—a definitive diagnosis may not be possible, resulting in the patient being categorized as having a cancer of unknown primary (CUP). Therapeutic options and clinical outcomes are poor for CUP patients, with a median survival of 8-11 months. Here we describe and validate the Tempus Tumor Origin (Tempus TO) assay, an RNA-seq-based machine learning classifier capable of discriminating between 68 clinically relevant cancer subtypes. We show that the Tempus TO model is 91% accurate when assessed on retrospectively and prospectively held out cohorts of containing 9,210 samples with known diagnoses. When evaluated on a cohort of CUPs, the model recapitulated established associations between genomic alterations and cancer subtype. Combining diagnostic prediction tests (e.g., Tempus TO) with sequencing-based variant reporting (e.g., Tempus xT) may expand therapeutic options for patients with cancers of unknown primary or uncertain histology.
Competing Interest Statement
All authors are employees, former employees, and/or hold restricted stock units of Tempus Labs, Inc.
Funding Statement
All authors are current or former employees of Tempus Labs, who provided funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All analyses were performed using de-identified data; IRB exemption Pro00042950 was obtained from Advarra on April 15, 2020.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
<jack.michuda{at}tempus.com>
<alessandra.breschi{at}tempus.com>
<joshuah.kapilivsky{at}tempus.com>
<kabir.manghnani{at}tempus.com>
<calvin.mccarter{at}tempus.com>
<adam.hockenberry{at}tempus.com>
<brittany.mineo{at}tempus.com>
<katie.igartua{at}tempus.com>
<joel.dudley{at}tempus.com>
<martin.stumpe{at}tempus.com>
<nike.beaubier{at}tempus.com>
<maryam.shirazi{at}tempus.com>
<ryan.jones{at}tempus.com>
<elizabeth.morency{at}tempus.com>
<kim.blackwell{at}tempus.com>
<justin.guinney{at}tempus.com>
Disclosure: All authors are employees, former employees, and/or hold restricted stock units of Tempus Labs, Inc.
Data Availability
Raw data for this study were generated at Tempus Labs. Derived data supporting the findings of this study are available within the paper and its Supplementary Figures/Tables or available from the authors upon request.
